881658-92-0

Basic information

• Product Name: 8-BROMO-2-METHOXY-1,5-NAPHTHYRIDINE
• Synonyms: 8-BROMO-2-METHOXY-1,5-NAPHTHYRIDINE;1,5-Naphthyridine, 8-broMo-2-Methoxy-;8-Bromo-2-methyloxy-1,5-naphthyridine
• CAS NO: 881658-92-0
• Molecular Formula: C₉H₇BrN₂O
• Molecular Weight: 239.06868
• Mol File: 881658-92-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 324.8±37.0 °C(Predicted)
• Appearance: /
• Density: 1.591±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.39±0.10(Predicted)
• CAS DataBase Reference: 8-BROMO-2-METHOXY-1,5-NAPHTHYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMO-2-METHOXY-1,5-NAPHTHYRIDINE(881658-92-0)
• EPA Substance Registry System: 8-BROMO-2-METHOXY-1,5-NAPHTHYRIDINE(881658-92-0)

Safety Data

• Hazardous Substances Data: 881658-92-0(Hazardous Substances Data)

Usage

General Description

8-BROMO-2-METHOXY-1,5-NAPHTHYRIDINE is a chemical compound with the molecular formula C12H9BrN2O. It is a naphthyridine derivative with a bromine atom and a methoxy group attached to the 2 and 5 positions, respectively. 8-BROMO-2-METHOXY-1,5-NAPHTHYRIDINE exhibits potential pharmacological properties and has been studied for its potential use in drug development. It may have applications in the fields of medicinal chemistry and pharmaceuticals, and further research is being conducted to better understand its properties and potential uses.

Upstream product

• 23443-25-6 6-methoxy-1,5-naphthyridin-4-ol 
• 23443-25-6 6-methoxy-1,5-naphthyridin-4(1H)-one 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 25063-69-8 5-[[(6-methoxypyridin-3-yl)amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione 

Downstream Products

• 1072792-50-7 3-(6-methoxy-[1,5]naphthyridin-4-yl)-prop-2-yn-1-ol 
• 1072793-11-3 [(S)-1-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)-ethyl]-carbamic acid benzyl ester 
• 1072827-92-9 4-(6-methoxy-[1,5]naphthyridin-4-yl)-3-oxo-piperazine-1-carboxylic acid tert-butyl ester 
• 1217296-47-3 8-[2-chloro-5-(trifluoromethyl)phenyl]-2-methoxy-1,5-naphthyridine 
• 1217296-41-7 8-(2-chlorophenyl)-2-methoxynaphthyridine 
• 1217296-46-2 8-(2,5-dichlorophenyl)-2-methoxy-1,5-naphthyridine 
• 1217296-44-0 8-(2,4-dichlorophenyl)-2-methoxy-1,5-naphthyridine 
• 1217296-48-4 C₁₅H₁₀Cl₂N₂O 
• 1217296-49-5 8-(2-chlorophenyl-6-methoxyphenyl)-2-methoxy-1,5-naphthyridine 
• 1217296-45-1 8-(2-chloro-4-methoxyphenyl)-2-methoxy-1,5-naphthyridine 
• 1217296-43-9 8-(2,3-dichlorophenyl)-2-methoxy-1,5-naphthyridine 
• 1242446-42-9 2-methoxy-8-(3-(trifluoromethyl)phenyl)-1,5-naphthyridine 
• 1072827-24-7 (RS)-{2-hydroxy-3-[4-(6-methoxy-[1,5]naphthyridin-4-yl)-piperazin-1-yl]-propyl}-carbamic acid benzyl ester 
• 1072826-48-2 (S)-3-(3-fluoro-4-methyl-phenyl)-2-oxo-oxazolidine-5-carboxylic acid [1-(6-methoxy-[1,5]naphthyridin-4-yl)-azetidin-3-ylmethyl]-amide 

Relevant articles and documents

Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria

A novel 2,8-disubstituted-1,5-naphthyridine hit compound stemming from the open access Medicines for Malaria Venture Pathogen Box formed a basis for a hit-to-lead medicinal chemistry program. Structure-activity relationship investigations resulted in compounds with potent antiplasmodial activity against both chloroquine sensitive (NF54) and multidrug resistant (K1) strains of the human malaria parasite Plasmodium falciparum. In the humanized P. falciparum mouse efficacy model, one of the frontrunner compounds showed in vivo efficacy at an oral dose of 4 × 50 mg·kg-1. In vitro mode-of-action studies revealed Plasmodium falciparum phosphatidylinositol-4-kinase as the target.

NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS

Compounds of Formula (I) wherein substituents R1, R2 and R5 are as defined, and Ar represents substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, furanyl, imidazolyl and thiophenyl substituted by a hydroxyalkyl substituent and an optional other substituent; compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

Compounds

Compounds of Formula (I), compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.